We are live on
!
Find out more
Federated Hermes Portfolio holdings
AUM
$69.6B
1-Year Est. Return
42.52%
This Fund
S&P 500
This Quarter
Est. Return
+5%
1 Year Est. Return
+42.52%
3 Year Est. Return
+132.48%
5 Year Est. Return
+152.58%
10 Year Est. Return
+652.43%
AUM
$40.3B
AUM Growth
+$535M
(+1.3%)
Cap. Flow
-$468M
Cap. Flow
% of AUM
-1.16%
Top 10 Holdings %
Top 10 Hldgs %
15.78%
Holding
2,279
New
170
Increased
711
Reduced
1,071
Closed
189
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Amgen
AMGN
|
+$178M |
| 2 |
LyondellBasell Industries
LYB
|
+$133M |
| 3 |
AT&T
T
|
+$124M |
| 4 |
Stanley Black & Decker
SWK
|
+$101M |
| 5 |
Pfizer
PFE
|
+$93.4M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Clorox
CLX
|
+$229M |
| 2 |
Gilead Sciences
GILD
|
+$164M |
| 3 |
Broadcom
AVGO
|
+$149M |
| 4 |
KeyCorp
KEY
|
+$145M |
| 5 |
Darden Restaurants
DRI
|
+$125M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 20.22% |
| 2 | Technology | 14.47% |
| 3 | Financials | 10.84% |
| 4 | Industrials | 9.01% |
| 5 | Consumer Discretionary | 8.84% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1076
Cognizant
CTSH
$27.9B
| $1.26M | ﹤0.01% |
19,229
-11,270
| -37% | -$698K |
|
1077
Cleveland-Cliffs
CLF
$6.93B
| $1.24M | ﹤0.01% |
74,263
-2,074
| -3% | -$32.9K |
|
1078
Donaldson
DCI
$10B
| $1.24M | ﹤0.01% |
19,800
+2,645
| +15% | +$165K |
|
1079
Annaly Capital Management
NLY
$16B
| $1.24M | ﹤0.01% |
61,829
-3,829
| -6% | -$74.4K |
|
1080
Range Resources
RRC
$9.08B
| $1.23M | ﹤0.01% |
41,959
-19,376
| -32% | -$527K |
|
1081
Waters Corp
WAT
$41.1B
| $1.21M | ﹤0.01% |
4,542
-543
| -11% | -$151K |
|
1082
VanEck Gold Miners ETF
GDX
$27.9B
| $1.2M | ﹤0.01% |
+40,000
| New | +$1.3M |
|
1083
Sally Beauty Holdings
SBH
$1.5B
| $1.19M | ﹤0.01% |
96,434
+1,717
| +2% | +$21.8K |
|
1084
Williams-Sonoma
WSM
$25.7B
| $1.19M | ﹤0.01% |
18,950
-432
| -2% | -$25.7K |
|
1085
RTX Corp
RTX
$265B
| $1.18M | ﹤0.01% |
12,074
+227
| +2% | +$22.2K |
|
1086
Protolabs
PRLB
$1.99B
| $1.18M | ﹤0.01% |
33,766
+604
| +2% | +$19.2K |
|
1087
Ribbon Communications
RBBN
$293M
| $1.18M | ﹤0.01% |
422,965
-218
| -0.1% | -$605 |
|
1088
American Financial Group
AFG
$11.9B
| $1.18M | ﹤0.01% |
9,916
-453
| -4% | -$53.4K |
|
|
TMHC
1089
DELISTED
Taylor Morrison
TMHC
| $1.17M | ﹤0.01% |
24,000
+3,416
| +17% | +$147K |
|
|
FLG
1090
Flagstar Bank National Association
FLG
$5.22B
| $1.17M | ﹤0.01% |
34,673
+1,059
| +3% | +$32.1K |
|
1091
TransDigm Group
TDG
$59.7B
| $1.16M | ﹤0.01% |
1,300
-6,092
| -82% | -$4.82M |
|
1092
Transmedics
TMDX
$3.04B
| $1.16M | ﹤0.01% |
13,813
-12,150
| -47% | -$930K |
|
1093
Performance Food Group
PFGC
$14.3B
| $1.16M | ﹤0.01% |
19,231
-726
| -4% | -$42.7K |
|
1094
Curtiss-Wright
CW
$21.1B
| $1.16M | ﹤0.01% |
6,296
-146
| -2% | -$24.9K |
|
|
BLD
1095
DELISTED
TopBuild
BLD
| $1.15M | ﹤0.01% |
4,332
-1,080
| -20% | -$237K |
|
1096
Middleby
MIDD
$5.08B
| $1.14M | ﹤0.01% |
7,741
-283
| -4% | -$39.9K |
|
1097
Patria Investments
PAX
$1.62B
| $1.14M | ﹤0.01% |
80,000
| – | – |
|
1098
Churchill Downs
CHDN
$5.76B
| $1.13M | ﹤0.01% |
8,109
-193
| -2% | -$26.4K |
|
1099
Gossamer Bio
GOSS
$67M
| $1.12M | ﹤0.01% |
11,716
-39
| -0.3% | -$3.89K |
|
1100
Townsquare Media
TSQ
$93.2M
| $1.12M | ﹤0.01% |
94,325
-40,890
| -30% | -$399K |
|
Similar funds
Federated Hermes's Q2 2023 Portfolio in Review
As of Q2 2023, Federated Hermes held 2,279 positions worth $40.3B, up 1.3% from $39.7B the previous quarter. Its ten largest holdings account for 16% of the portfolio.
Federated Hermes's Q2 2023 filing shows 170 new, 711 increased, 1,071 reduced and 189 closed positions. Its largest new stake was HashiCorp, Inc. Class A Common Stock: 1,317,400 shares worth $34.5M. The largest sale was Clorox, an estimated $229M.
By sector, the portfolio is most concentrated in Healthcare at 20% of assets, up from 20% a quarter earlier, followed by Technology and Financials.
- Federated Hermes's largest Q2 2023 buy was HashiCorp, Inc. Class A Common Stock: 1,317,400 shares worth $34.5M.
- Federated Hermes added most to Amgen in Q2 2023, an estimated $178M increase.
- Federated Hermes's biggest Q2 2023 reduction was Clorox, cutting an estimated $229M.
- Federated Hermes fully exited Prometheus Biosciences, Inc. Common Stock in Q2 2023, selling an estimated $55.4M.
- Federated Hermes's ten largest holdings make up 16% of its $40.3B portfolio in Q2 2023.
- Federated Hermes opened 170 new positions and closed 189 in Q2 2023.
- Federated Hermes's portfolio value rose 1.3% quarter-over-quarter to $40.3B.
Based on Federated Hermes's 13F filing for Q2 2023, filed 14 Aug 2023.